JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA

• LSL Pharma’s wholly‑owned subsidiary Juno OTC signed a binding term sheet with Instapill Private Ltd. to supply private‑label Loratadine 10 mg rapid‑dissolve tablets (RDT) to Canadian retailers.
• The product is bioequivalent to Claritin RDT and targets the ~CAD 60 M Canadian OTC allergy market, which is growing ≈8 % YoY.
• Commercial launch is slated for June 2027, subject to Health Canada approval.
• This follows Juno’s earlier private‑label Loperamide 2 mg RDT launch and builds on the acquisition of Juno OTC (closed Dec 2025).
• Management frames the deal as a validation of its “private‑label rapid‑dissolve” commercialization model and a step toward its goal of 10 new product launches within 12 months.

• Expectation vs. reality: The partnership was anticipated after the Juno acquisition; analysts had already priced in pipeline expansion. Consequently, the news is incremental, not a surprise.
• Revenue potential: $60 M market size with ~8 % growth suggests modest incremental revenue once launched (likely low‑single‑digit millions annually). The impact on near‑term earnings is minimal because launch is more than a year away and contingent on regulatory clearance.
• Strategic fit: Strengthens Juno’s RDT platform, diversifies beyond Loperamide, and deepens the Canadian retail footprint—positive but routine given prior guidance.
• Risk factors: Health Canada approval remains uncertain; execution risk around manufacturing scale‑up and retailer adoption could delay or reduce upside.

Overall materiality: The announcement is a routine positive development – it confirms strategic direction without materially altering valuation or risk profile.

LSL Pharma Group Inc. is an integrated Canadian pharmaceutical company focused on:
- Sterile ophthalmic products (FDA‑certified manufacturing, Health Canada approvals).
- OTC rapid‑dissolve tablets via its Juno OTC subsidiary (private‑label model).
Flagship projects include the FDA‑certified ophthalmic ointment line (Avaclyr®) and the expanding Juno RDT portfolio (Loperamide, now Loratadine).